Note: This on-demand video is not available for CME/CNE credit.
Acute myeloid leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment.
The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML.
Presentation Objectives
At the conclusion of this educational initiative, participants should be able to:
- Recall new data on investigational agents for AML and evolving evidence based guidelines and current understanding of treatment outcomes among older patients with AML
- Recognize new data regarding the screening and management of older patients with AML
- Employ an electronic screening tool in clinic to evaluate frailty status among older patients newly diagnosed AML or those needing a new line of therapy
Faculty
Thomas W. LeBlanc, MD
Associate Professor of Medicine Duke Cancer Institute
Ashley Leak Bryant, PhD, RN-BC, OCN
University North Carolina Lineberger Comprehensive Cancer Center
